On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – SeeThruEquity Issues Update on Nephros, Inc. (NEPH), PT Steady at $1.65

Company: Nephros, Inc. (NEPH)
Category: Analyst Alerts

SeeThruEquity recently updated its coverage and price target of $1.65 on Nephros (OTCQB: NEPH) common stock. In its financial results for the three months and full-year ended December 31, 2016, Nephros reported full-year revenue growth of 19% to $2.3 million, among other financial highlights of the year. Product updates include receiving 510(k) clearance for new 10″ filters for HydraGuard™ for infection control and EndoPur™ for hemodialysis. The company plans to launch the product in the second quarter of 2017. Nephros said it expects to grow product revenues by 100% in 2017 and set a goal of reaching cash flow breakeven by mid-2017. “We view Nephros as an intriguing high risk / high reward investment opportunity in the medical instruments industry with several potential catalysts in 2017 stemming from growth from new product launches and guidance for reaching cash flow breakeven in the next six months,” writes SeeThruEquity.

To view the full press release, visit http://nnw.fm/z8Et3

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients. For more information, visit www.nephros.com

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217